## Tango Therapeutics (TNGX) — filings-led deep dive (SEC primary) ### 0) “Choose-your-path” map (you don’t need to respond) You can skim the **Executive Takeaway**, then jump to the sections you care about most: 1) **Business & pipeline** (what they’re building) 2) **Funding & runway** (how long cash lasts / what changed recently) 3) **Gilead collaboration economics** (value drivers & constraints) 4) **Governance & incentives** (CEO change + exec comp alignment) 5) **Risk register** (what can break the story) --- ## 1) Executive takeaway (what matters most) Tango frames itself as a **precision oncology** company targeting **tumor suppressor gene loss** using **synthetic lethality**, with a clinical focus on **PRMT5 inhibitors** (TNG462, TNG456) and an immuno-oncology angle via **CoREST inhibition** (TNG260). ["precision oncology company"](0001193125-25-263680|0) ["synthetic lethality"](0000950170-25-028353|0) ["PRMT5 inhibitors"](0000950170-25-028353|0) ["CoREST inhibitor"](0000950170-25-028353|0) Financially, the company reported **FY2024 net loss of $130.3m** and **FY2024 R&D of $143.9m**, but also reports a meaningful non-dilutive/partnering component via **Gilead** and other license revenue. ["Net loss"](0000950170-25-028353|0) ["Research and development"](0000950170-25-028353|0) ["Collaboration revenue"](0000950170-25-028353|0) On liquidity: at **Sep 30, 2025**, Tango reported **$152.8m** of cash + marketable securities, then raised **$212.0m net** in October 2025 and stated this combined pool should fund operations **into 2028** (company estimate). ["cash and cash equivalents and marketable securities of $152.8 million"](0001193125-25-263680|0) ["net proceeds were $212.0 million"](0001193125-25-263680|0) ["will enable us to fund"](0001193125-25-263680|0) Governance changed recently: **CEO Barbara Weber retired effective Jan 8, 2026; Malte Peters appointed President & CEO effective immediately**; Weber becomes **Executive Chair for 2026**. ["retirement of its Chief Executive Officer"](0001193125-26-007086|4) ["appointed President and Chief Executive Officer"](0001193125-26-007086|4) ["become Executive Chair"](0001193125-26-007086|4) --- ## 2) Business model & scientific thesis (from the 10-K) ### What they say they do Tango’s stated mission is to discover targeted oncology therapies by exploiting vulnerabilities created by **tumor suppressor gene loss**, using **synthetic lethality** (selective killing of altered cancer cells while sparing normal cells). ["tumor suppressor gene loss"](0000950170-25-028353|0) ["synthetic lethality"](0000950170-25-028353|0) ["sparing normal cells"](0000950170-25-028353|0) ### Why this matters strategically Their thesis is that “classic” targeted therapy often goes after **oncogenes**, but **tumor suppressor loss** is “undruggable” directly—so the commercial/clinical opportunity is in finding partner dependencies (synthetic lethal targets) and pairing that with biomarker-driven enrollment. ["cannot be directly targeted"](0000950170-25-028353|0) ["patient selection marker"](0000950170-25-028353|0) --- ## 3) Pipeline: what’s in the clinic (and what was stopped) ### Pipeline snapshot (filings-derived) | Program | Modality / target | Lead clinical intent (as described) | Status callouts in filings | |---|---|---|---| | TNG462 | MTA-cooperative PRMT5 inhibitor | Non‑CNS MTAP‑deleted cancers; focus includes pancreatic & lung; plans include monotherapy + combinations | “currently developing… TNG462” ["TNG462"](0000950170-25-028353|0) | | TNG456 | Brain‑penetrant PRMT5 inhibitor | CNS cancers incl. GBM; FDA cleared IND Jan 2025; plans to begin Phase 1/2 in 1H 2025 | “FDA cleared the TNG456 IND” ["cleared the TNG456 IND"](0000950170-25-028353|0) | | TNG260 | CoREST inhibitor | STK11‑mutant tumors (lung focus) in combination with anti‑PD‑1 | “TNG260 is a first‑in‑class CoREST inhibitor” ["first-in-class CoREST"](0000950170-25-028353|0) | | TNG908 | Brain‑penetrant PRMT5 inhibitor (prior) | GBM focus did not show RANO responses; enrollment stopped; program discontinued to prioritize TNG462/TNG456 | “stopped enrollment… discontinued” ["stopped enrollment"](0000950170-25-028353|0) | | TNG348 | USP1 inhibitor (prior) | Discontinued (toxicity in dose escalation) | “discontinuation of TNG348” ["discontinuation of TNG348"](0000950170-25-028353|0) | ### How Tango describes prioritization They explicitly say they **discontinued TNG908** to “fully resource” TNG462 and TNG456 (portfolio focus). ["discontinued further development"](0000950170-25-028353|0) --- ## 4) Collaborations & economic engine: Gilead (plus how revenue is recognized) ### 4.1 Gilead deal terms (the “shape” of the partnership) Tango discloses that the **Gilead Agreement** runs through a **seven-year research term ending Aug 2027**, with Gilead options to license **up to 15 targets**. ["seven-year period ending in August 2027"](0000950170-25-028353|0) ["up to 15 targets"](0000950170-25-028353|0) Key economics disclosed: - Upfront cash: **$125.0m** (plus **$50.0m** under the 2018 agreement). ["upfront payment of $125.0 million"](0000950170-25-028353|0) ["upfront payment of $50.0 million"](0000950170-25-028353|0) - Equity investment: **$20.0m**. ["$20.0 million equity investment"](0000950170-25-028353|0) - Fees received (as of Dec 31, 2024): **$38.2m license fees** and **$24.0m research extension fees**. ["received $38.2 million in license fees"](0000950170-25-028353|0) ["$24.0 million in research extension fees"](0000950170-25-028353|0) - Potential milestones: **up to $410.0m per program**. ["up to an additional $410.0 million per program"](0000950170-25-028353|0) - Royalties: **tiered royalties in the first decile** on net sales (ex‑U.S., as described). ["tiered royalties in the first decile"](0000950170-25-028353|0) - Optional U.S. co-dev/co-promote for up to 5 programs with **50/50 U.S. profits/losses** and cost share for U.S.-attributable development costs. ["option to co-develop and co-promote"](0000950170-25-028353|0) ["equally split profits and losses"](0000950170-25-028353|0) **Interpretation (why this matters):** this structure can create “step-function” valuation inflections (license fees, milestones), but it also means parts of the pipeline’s upside depend on **Gilead exercising options and advancing programs**. ### 4.2 Accounting nuance: collaboration vs license revenue Tango explains collaboration revenue recognition under ASC 606 with a **single combined performance obligation** (research services + steering committee participation) for the Gilead agreement, while **license fees are recognized immediately** when Tango has no continued involvement and the license is distinct. ["single combined performance obligation"](0000950170-25-028353|0) ["License fees are recognized as revenue immediately"](0000950170-25-028353|0) --- ## 5) Financial performance (filings tables) ### 5.1 Income statement (FY 2022–2024, USD millions) (Scale: USD **millions**, computed from “in thousands” figures.) | Metric | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Total revenue | $42.07 ["Total revenue"](0000950170-25-028353|0) | $36.53 ["Total revenue"](0000950170-25-028353|0) | $24.86 ["Total revenue"](0000950170-25-028353|0) | | R&D expense | $143.92 ["Research and development"](0000950170-25-028353|0) | $115.20 ["Research and development"](0000950170-25-028353|0) | $105.91 ["Research and development"](0000950170-25-028353|0) | | G&A expense | $43.75 ["General and administrative"](0000950170-25-028353|0) | $35.50 ["General and administrative"](0000950170-25-028353|0) | $30.03 ["General and administrative"](0000950170-25-028353|0) | | Net loss | $(130.30) ["Net loss"](0000950170-25-028353|0) | $(101.74) ["Net loss"](0000950170-25-028353|0) | $(108.18) ["Net loss"](0000950170-25-028353|0) | ### 5.2 Balance sheet & capital structure markers (FY-end 2024 vs Sep 30, 2025) (Scale: USD **millions** (computed), except shares.) | Metric | Dec 31, 2024 | Sep 30, 2025 | |---|---:|---:| | Cash & cash equivalents | $69.53 ["Cash and cash equivalents"](0000950170-25-028353|0) | $58.34 ["Cash and cash equivalents"](0001193125-25-263680|0) | | Marketable securities | $188.39 ["Marketable securities"](0000950170-25-028353|0) | $94.47 ["Marketable securities"](0001193125-25-263680|0) | | Cash + marketable securities | $257.92 (computed) ["Cash and cash equivalents"](0000950170-25-028353|0) ["Marketable securities"](0000950170-25-028353|0) | $152.81 (computed) ["Cash and cash equivalents"](0001193125-25-263680|0) ["Marketable securities"](0001193125-25-263680|0) | | Total assets | $316.49 ["Total assets"](0000950170-25-028353|0) | $210.14 ["Total assets"](0001193125-25-263680|0) | | Shares outstanding | 107,729,343 ["shares issued and outstanding"](0000950170-25-028353|0) | 111,567,062 ["shares issued and outstanding"](0001193125-25-263680|0) | --- ## 6) Liquidity & runway (the key “survivability” disclosures) ### 6.1 Runway statements (company guidance in filings) - As of **Dec 31, 2024**, Tango said cash + marketable securities of **$257.9m** funds operations **at least into Q3 2026**. ["cash, cash equivalents and marketable securities on hand as of December 31, 2024 of $257.9 million"](0000950170-25-028353|0) ["at least into the third quarter of 2026"](0000950170-25-028353|0) - As of **Sep 30, 2025**, Tango said cash + marketable securities of **$152.8m** plus **$212.0m net proceeds** from the Oct 2025 offering should fund operations **into 2028**. ["cash and cash equivalents and marketable securities of $152.8 million"](0001193125-25-263680|0) ["net proceeds were $212.0 million"](0001193125-25-263680|0) ["will enable us to fund"](0001193125-25-263680|0) ### 6.2 What changed: Oct 2025 financing details They disclosed issuance of **22,755,438 common shares at $8.66** plus **3,226,458 pre-funded warrants** at $8.659, for **$225.0m gross**, **$212.0m net**, closing **Oct 24, 2025**. ["22,755,438 shares"](0001193125-25-263680|0) ["$225.0 million"](0001193125-25-263680|0) ["Both transactions closed on October 24, 2025"](0001193125-25-263680|0) **Pro forma liquidity lens:** $152.8m (Sep 30, 2025 cash+securities) + $212.0m net proceeds = **$364.8m** (computed), before any Q4 burn. ["cash and cash equivalents and marketable securities of $152.8 million"](0001193125-25-263680|0) ["net proceeds were $212.0 million"](0001193125-25-263680|0) --- ## 7) Governance & incentives: management change + executive comp signals ### 7.1 CEO transition (Jan 2026) Tango disclosed: - CEO **Barbara Weber** retired effective **Jan 8, 2026**. ["effective today January 8, 2026"](0001193125-26-007086|4) - **Malte Peters** appointed **President and CEO**, effective immediately. ["appointed President and Chief Executive Officer"](0001193125-26-007086|4) - Weber becomes **Executive Chair for 2026**, then **non-executive chair starting 2027**; and the prior board chair transitions to **Lead Independent Director**. ["become Executive Chair for 2026"](0001193125-26-007086|4) ["Lead Independent Director"](0001193125-26-007086|4) ### 7.2 Executive pay structure (Proxy statement) From the 2025 proxy (covering 2024 comp), Tango lists the named executive officers (NEOs) and provides base salary and equity grant disclosure. ["named executive officers"](0000950170-25-056230|0) **Base salary (NEOs)** | Name | 2023 base salary | 2024 base salary | |---|---:|---:| | Barbara Weber (CEO) | $627,000 ["Barbara Weber, M.D."](0000950170-25-056230|0) | $660,000 ["660,000"](0000950170-25-056230|0) | | Daniella Beckman (CFO) | $442,100 ["Daniella Beckman"](0000950170-25-056230|0) | $486,314 ["486,314"](0000950170-25-056230|0) | | Adam Crystal (President R&D) | $550,000 ["Adam Crystal"](0000950170-25-056230|0) | $569,250 ["569,250"](0000950170-25-056230|0) | | Douglas Barry (Chief Legal Officer) | $435,942 ["Douglas Barry"](0000950170-25-056230|0) | $451,200 ["451,200"](0000950170-25-056230|0) | **Equity granted in 2024 (NEOs)** | Name | Options granted (shares) | Stock awards / RSUs granted (shares) | |---|---:|---:| | Barbara Weber | 523,012 ["523,012"](0000950170-25-056230|0) | 87,168 ["87,168"](0000950170-25-056230|0) | | Daniella Beckman | 236,475 ["236,475"](0000950170-25-056230|0) | 39,413 ["39,413"](0000950170-25-056230|0) | | Adam Crystal | 279,593 ["279,593"](0000950170-25-056230|0) | 46,599 ["46,599"](0000950170-25-056230|0) | | Douglas Barry | 137,156 ["137,156"](0000950170-25-056230|0) | 22,859 ["22,859"](0000950170-25-056230|0) | **Interpretation (alignment):** Tango emphasizes a mix of **cash + long-term equity**, with equity vesting schedules designed to retain executives and align with stockholders (per CD&A narrative). ["balance between cash and equity"](0000950170-25-056230|0) --- ## 8) Risk register (filings-driven, the “what can go wrong” checklist) ### 8.1 Manufacturing/supply chain concentration (high-impact) Tango discloses reliance on limited third parties for manufacturing and highlights that **an affiliate of WuXi AppTec is the sole source of API for all clinical-stage product candidates**, with mention of proposed U.S. legislation that could restrict business with WuXi. ["sole source of API"](0000950170-25-028353|0) ["WuXi AppTec"](0000950170-25-028353|0) ["proposed Congressional legislation"](0000950170-25-028353|0) ### 8.2 Clinical & development risk (core biotech risk) They state they have **no products approved** and product development is highly uncertain and expensive. ["no products approved"](0000950170-25-028353|0) ### 8.3 Funding & dilution risk (always present, even with runway statements) They explicitly note the need to raise additional funding and that runway estimates depend on assumptions that could be wrong. ["We will need to raise substantial additional funding"](0000950170-25-028353|0) ["assumptions that may prove to be wrong"](0000950170-25-028353|0) --- ## 9) A few “analyst-style” angles to pressure-test the story (optional reading) 1) **Pipeline focus vs. portfolio churn:** They discontinued **TNG908** and **TNG348**, which is a rational capital allocation signal—but it also highlights that the platform can generate clinical assets that don’t clear the bar. ["discontinued further development"](0000950170-25-028353|0) ["discontinuation of TNG348"](0000950170-25-028353|0) 2) **Partnering leverage:** Gilead economics provide meaningful optionality (licenses/milestones/royalties), but outcomes depend on **Gilead’s decisions** and the success of those programs. ["Gilead has the option"](0000950170-25-028353|0) 3) **Runway is strong *per filings*, but execution dominates:** They now guide to funding “into 2028” after the Oct 2025 raise; the key is whether spend accelerates (more trials, combinations, manufacturing scale-up). ["into 2028"](0001193125-25-263680|0) --- ### Source set used (all SEC) - FY2024 10-K: (0000950170-25-028353|0) - Q3 2025 10-Q: (0001193125-25-263680|0) - 8-K press release (CEO transition): (0001193125-26-007086|4) - 2025 proxy (NEO comp): (0000950170-25-056230|0)

## Tango Therapeutics (TNGX) — filings-led deep dive (SEC primary) ### 0) “Choose-your-path” map (you don’t need to respond) You can skim the **Executive Takeaway**, then jump to the sections you care about most: 1) **Business & pipeline** (what they’re building) 2) **Funding & runway** (how long cash lasts / what changed recently) 3) **Gilead collaboration economics** (value drivers & constraints) 4) **Governance & incentives** (CEO change + exec comp alignment) 5) **Risk register** (what can break the story) --- ## 1) Executive takeaway (what matters most) Tango frames itself as a **precision oncology** company targeting **tumor suppressor gene loss** using **synthetic lethality**, with a clinical focus on **PRMT5 inhibitors** (TNG462, TNG456) and an immuno-oncology angle via **CoREST inhibition** (TNG260). ["precision oncology company"](0001193125-25-263680|0) ["synthetic lethality"](0000950170-25-028353|0) ["PRMT5 inhibitors"](0000950170-25-028353|0) ["CoREST inhibitor"](0000950170-25-028353|0) Financially, the company reported **FY2024 net loss of $130.3m** and **FY2024 R&D of $143.9m**, but also reports a meaningful non-dilutive/partnering component via **Gilead** and other license revenue. ["Net loss"](0000950170-25-028353|0) ["Research and development"](0000950170-25-028353|0) ["Collaboration revenue"](0000950170-25-028353|0) On liquidity: at **Sep 30, 2025**, Tango reported **$152.8m** of cash + marketable securities, then raised **$212.0m net** in October 2025 and stated this combined pool should fund operations **into 2028** (company estimate). ["cash and cash equivalents and marketable securities of $152.8 million"](0001193125-25-263680|0) ["net proceeds were $212.0 million"](0001193125-25-263680|0) ["will enable us to fund"](0001193125-25-263680|0) Governance changed recently: **CEO Barbara Weber retired effective Jan 8, 2026; Malte Peters appointed President & CEO effective immediately**; Weber becomes **Executive Chair for 2026**. ["retirement of its Chief Executive Officer"](0001193125-26-007086|4) ["appointed President and Chief Executive Officer"](0001193125-26-007086|4) ["become Executive Chair"](0001193125-26-007086|4) --- ## 2) Business model & scientific thesis (from the 10-K) ### What they say they do Tango’s stated mission is to discover targeted oncology therapies by exploiting vulnerabilities created by **tumor suppressor gene loss**, using **synthetic lethality** (selective killing of altered cancer cells while sparing normal cells). ["tumor suppressor gene loss"](0000950170-25-028353|0) ["synthetic lethality"](0000950170-25-028353|0) ["sparing normal cells"](0000950170-25-028353|0) ### Why this matters strategically Their thesis is that “classic” targeted therapy often goes after **oncogenes**, but **tumor suppressor loss** is “undruggable” directly—so the commercial/clinical opportunity is in finding partner dependencies (synthetic lethal targets) and pairing that with biomarker-driven enrollment. ["cannot be directly targeted"](0000950170-25-028353|0) ["patient selection marker"](0000950170-25-028353|0) --- ## 3) Pipeline: what’s in the clinic (and what was stopped) ### Pipeline snapshot (filings-derived) | Program | Modality / target | Lead clinical intent (as described) | Status callouts in filings | |---|---|---|---| | TNG462 | MTA-cooperative PRMT5 inhibitor | Non‑CNS MTAP‑deleted cancers; focus includes pancreatic & lung; plans include monotherapy + combinations | “currently developing… TNG462” ["TNG462"](0000950170-25-028353|0) | | TNG456 | Brain‑penetrant PRMT5 inhibitor | CNS cancers incl. GBM; FDA cleared IND Jan 2025; plans to begin Phase 1/2 in 1H 2025 | “FDA cleared the TNG456 IND” ["cleared the TNG456 IND"](0000950170-25-028353|0) | | TNG260 | CoREST inhibitor | STK11‑mutant tumors (lung focus) in combination with anti‑PD‑1 | “TNG260 is a first‑in‑class CoREST inhibitor” ["first-in-class CoREST"](0000950170-25-028353|0) | | TNG908 | Brain‑penetrant PRMT5 inhibitor (prior) | GBM focus did not show RANO responses; enrollment stopped; program discontinued to prioritize TNG462/TNG456 | “stopped enrollment… discontinued” ["stopped enrollment"](0000950170-25-028353|0) | | TNG348 | USP1 inhibitor (prior) | Discontinued (toxicity in dose escalation) | “discontinuation of TNG348” ["discontinuation of TNG348"](0000950170-25-028353|0) | ### How Tango describes prioritization They explicitly say they **discontinued TNG908** to “fully resource” TNG462 and TNG456 (portfolio focus). ["discontinued further development"](0000950170-25-028353|0) --- ## 4) Collaborations & economic engine: Gilead (plus how revenue is recognized) ### 4.1 Gilead deal terms (the “shape” of the partnership) Tango discloses that the **Gilead Agreement** runs through a **seven-year research term ending Aug 2027**, with Gilead options to license **up to 15 targets**. ["seven-year period ending in August 2027"](0000950170-25-028353|0) ["up to 15 targets"](0000950170-25-028353|0) Key economics disclosed: - Upfront cash: **$125.0m** (plus **$50.0m** under the 2018 agreement). ["upfront payment of $125.0 million"](0000950170-25-028353|0) ["upfront payment of $50.0 million"](0000950170-25-028353|0) - Equity investment: **$20.0m**. ["$20.0 million equity investment"](0000950170-25-028353|0) - Fees received (as of Dec 31, 2024): **$38.2m license fees** and **$24.0m research extension fees**. ["received $38.2 million in license fees"](0000950170-25-028353|0) ["$24.0 million in research extension fees"](0000950170-25-028353|0) - Potential milestones: **up to $410.0m per program**. ["up to an additional $410.0 million per program"](0000950170-25-028353|0) - Royalties: **tiered royalties in the first decile** on net sales (ex‑U.S., as described). ["tiered royalties in the first decile"](0000950170-25-028353|0) - Optional U.S. co-dev/co-promote for up to 5 programs with **50/50 U.S. profits/losses** and cost share for U.S.-attributable development costs. ["option to co-develop and co-promote"](0000950170-25-028353|0) ["equally split profits and losses"](0000950170-25-028353|0) **Interpretation (why this matters):** this structure can create “step-function” valuation inflections (license fees, milestones), but it also means parts of the pipeline’s upside depend on **Gilead exercising options and advancing programs**. ### 4.2 Accounting nuance: collaboration vs license revenue Tango explains collaboration revenue recognition under ASC 606 with a **single combined performance obligation** (research services + steering committee participation) for the Gilead agreement, while **license fees are recognized immediately** when Tango has no continued involvement and the license is distinct. ["single combined performance obligation"](0000950170-25-028353|0) ["License fees are recognized as revenue immediately"](0000950170-25-028353|0) --- ## 5) Financial performance (filings tables) ### 5.1 Income statement (FY 2022–2024, USD millions) (Scale: USD **millions**, computed from “in thousands” figures.) | Metric | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Total revenue | $42.07 ["Total revenue"](0000950170-25-028353|0) | $36.53 ["Total revenue"](0000950170-25-028353|0) | $24.86 ["Total revenue"](0000950170-25-028353|0) | | R&D expense | $143.92 ["Research and development"](0000950170-25-028353|0) | $115.20 ["Research and development"](0000950170-25-028353|0) | $105.91 ["Research and development"](0000950170-25-028353|0) | | G&A expense | $43.75 ["General and administrative"](0000950170-25-028353|0) | $35.50 ["General and administrative"](0000950170-25-028353|0) | $30.03 ["General and administrative"](0000950170-25-028353|0) | | Net loss | $(130.30) ["Net loss"](0000950170-25-028353|0) | $(101.74) ["Net loss"](0000950170-25-028353|0) | $(108.18) ["Net loss"](0000950170-25-028353|0) | ### 5.2 Balance sheet & capital structure markers (FY-end 2024 vs Sep 30, 2025) (Scale: USD **millions** (computed), except shares.) | Metric | Dec 31, 2024 | Sep 30, 2025 | |---|---:|---:| | Cash & cash equivalents | $69.53 ["Cash and cash equivalents"](0000950170-25-028353|0) | $58.34 ["Cash and cash equivalents"](0001193125-25-263680|0) | | Marketable securities | $188.39 ["Marketable securities"](0000950170-25-028353|0) | $94.47 ["Marketable securities"](0001193125-25-263680|0) | | Cash + marketable securities | $257.92 (computed) ["Cash and cash equivalents"](0000950170-25-028353|0) ["Marketable securities"](0000950170-25-028353|0) | $152.81 (computed) ["Cash and cash equivalents"](0001193125-25-263680|0) ["Marketable securities"](0001193125-25-263680|0) | | Total assets | $316.49 ["Total assets"](0000950170-25-028353|0) | $210.14 ["Total assets"](0001193125-25-263680|0) | | Shares outstanding | 107,729,343 ["shares issued and outstanding"](0000950170-25-028353|0) | 111,567,062 ["shares issued and outstanding"](0001193125-25-263680|0) | --- ## 6) Liquidity & runway (the key “survivability” disclosures) ### 6.1 Runway statements (company guidance in filings) - As of **Dec 31, 2024**, Tango said cash + marketable securities of **$257.9m** funds operations **at least into Q3 2026**. ["cash, cash equivalents and marketable securities on hand as of December 31, 2024 of $257.9 million"](0000950170-25-028353|0) ["at least into the third quarter of 2026"](0000950170-25-028353|0) - As of **Sep 30, 2025**, Tango said cash + marketable securities of **$152.8m** plus **$212.0m net proceeds** from the Oct 2025 offering should fund operations **into 2028**. ["cash and cash equivalents and marketable securities of $152.8 million"](0001193125-25-263680|0) ["net proceeds were $212.0 million"](0001193125-25-263680|0) ["will enable us to fund"](0001193125-25-263680|0) ### 6.2 What changed: Oct 2025 financing details They disclosed issuance of **22,755,438 common shares at $8.66** plus **3,226,458 pre-funded warrants** at $8.659, for **$225.0m gross**, **$212.0m net**, closing **Oct 24, 2025**. ["22,755,438 shares"](0001193125-25-263680|0) ["$225.0 million"](0001193125-25-263680|0) ["Both transactions closed on October 24, 2025"](0001193125-25-263680|0) **Pro forma liquidity lens:** $152.8m (Sep 30, 2025 cash+securities) + $212.0m net proceeds = **$364.8m** (computed), before any Q4 burn. ["cash and cash equivalents and marketable securities of $152.8 million"](0001193125-25-263680|0) ["net proceeds were $212.0 million"](0001193125-25-263680|0) --- ## 7) Governance & incentives: management change + executive comp signals ### 7.1 CEO transition (Jan 2026) Tango disclosed: - CEO **Barbara Weber** retired effective **Jan 8, 2026**. ["effective today January 8, 2026"](0001193125-26-007086|4) - **Malte Peters** appointed **President and CEO**, effective immediately. ["appointed President and Chief Executive Officer"](0001193125-26-007086|4) - Weber becomes **Executive Chair for 2026**, then **non-executive chair starting 2027**; and the prior board chair transitions to **Lead Independent Director**. ["become Executive Chair for 2026"](0001193125-26-007086|4) ["Lead Independent Director"](0001193125-26-007086|4) ### 7.2 Executive pay structure (Proxy statement) From the 2025 proxy (covering 2024 comp), Tango lists the named executive officers (NEOs) and provides base salary and equity grant disclosure. ["named executive officers"](0000950170-25-056230|0) **Base salary (NEOs)** | Name | 2023 base salary | 2024 base salary | |---|---:|---:| | Barbara Weber (CEO) | $627,000 ["Barbara Weber, M.D."](0000950170-25-056230|0) | $660,000 ["660,000"](0000950170-25-056230|0) | | Daniella Beckman (CFO) | $442,100 ["Daniella Beckman"](0000950170-25-056230|0) | $486,314 ["486,314"](0000950170-25-056230|0) | | Adam Crystal (President R&D) | $550,000 ["Adam Crystal"](0000950170-25-056230|0) | $569,250 ["569,250"](0000950170-25-056230|0) | | Douglas Barry (Chief Legal Officer) | $435,942 ["Douglas Barry"](0000950170-25-056230|0) | $451,200 ["451,200"](0000950170-25-056230|0) | **Equity granted in 2024 (NEOs)** | Name | Options granted (shares) | Stock awards / RSUs granted (shares) | |---|---:|---:| | Barbara Weber | 523,012 ["523,012"](0000950170-25-056230|0) | 87,168 ["87,168"](0000950170-25-056230|0) | | Daniella Beckman | 236,475 ["236,475"](0000950170-25-056230|0) | 39,413 ["39,413"](0000950170-25-056230|0) | | Adam Crystal | 279,593 ["279,593"](0000950170-25-056230|0) | 46,599 ["46,599"](0000950170-25-056230|0) | | Douglas Barry | 137,156 ["137,156"](0000950170-25-056230|0) | 22,859 ["22,859"](0000950170-25-056230|0) | **Interpretation (alignment):** Tango emphasizes a mix of **cash + long-term equity**, with equity vesting schedules designed to retain executives and align with stockholders (per CD&A narrative). ["balance between cash and equity"](0000950170-25-056230|0) --- ## 8) Risk register (filings-driven, the “what can go wrong” checklist) ### 8.1 Manufacturing/supply chain concentration (high-impact) Tango discloses reliance on limited third parties for manufacturing and highlights that **an affiliate of WuXi AppTec is the sole source of API for all clinical-stage product candidates**, with mention of proposed U.S. legislation that could restrict business with WuXi. ["sole source of API"](0000950170-25-028353|0) ["WuXi AppTec"](0000950170-25-028353|0) ["proposed Congressional legislation"](0000950170-25-028353|0) ### 8.2 Clinical & development risk (core biotech risk) They state they have **no products approved** and product development is highly uncertain and expensive. ["no products approved"](0000950170-25-028353|0) ### 8.3 Funding & dilution risk (always present, even with runway statements) They explicitly note the need to raise additional funding and that runway estimates depend on assumptions that could be wrong. ["We will need to raise substantial additional funding"](0000950170-25-028353|0) ["assumptions that may prove to be wrong"](0000950170-25-028353|0) --- ## 9) A few “analyst-style” angles to pressure-test the story (optional reading) 1) **Pipeline focus vs. portfolio churn:** They discontinued **TNG908** and **TNG348**, which is a rational capital allocation signal—but it also highlights that the platform can generate clinical assets that don’t clear the bar. ["discontinued further development"](0000950170-25-028353|0) ["discontinuation of TNG348"](0000950170-25-028353|0) 2) **Partnering leverage:** Gilead economics provide meaningful optionality (licenses/milestones/royalties), but outcomes depend on **Gilead’s decisions** and the success of those programs. ["Gilead has the option"](0000950170-25-028353|0) 3) **Runway is strong *per filings*, but execution dominates:** They now guide to funding “into 2028” after the Oct 2025 raise; the key is whether spend accelerates (more trials, combinations, manufacturing scale-up). ["into 2028"](0001193125-25-263680|0) --- ### Source set used (all SEC) - FY2024 10-K: (0000950170-25-028353|0) - Q3 2025 10-Q: (0001193125-25-263680|0) - 8-K press release (CEO transition): (0001193125-26-007086|4) - 2025 proxy (NEO comp): (0000950170-25-056230|0)